Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701515 | 1.00 | FFAR3 (0.33) | FFAR3NPSR1MAPTROCK2ROCK1 | |
| SCHEMBL1468235 | 1.00 | FFAR3 (0.33) | FFAR3NPSR1MAPTROCK2ROCK1 | |
| SCHEMBL20000455 | 0.85 | FFAR3 (0.33) | FFAR3NPSR1MAPTLMNA | |
| SCHEMBL2702145 | 0.80 | BRD4 (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL1468125 | 0.80 | BRD4 (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL2700331 | 0.80 | BRD4 (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL8175853 | 0.78 | FFAR3 (0.50) | FFAR3NPSR1MAPTMEN1CYP3A4 | |
| SCHEMBL25616531 | 0.78 | FFAR3 (0.50) | FFAR3NPSR1MAPTMEN1CYP3A4 | |
| SCHEMBL283125 | 0.78 | — | — | |
| SCHEMBL25616533 | 0.78 | FFAR3 (0.50) | FFAR3NPSR1MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450333-B1 | METHOD FOR PRODUCING ALICYCLIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-8816136-B2 | Method for producing alicyclic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20120238784-A1 | METHOD FOR PRODUCING ALICYCLIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-09-20 | — | — | US | disclosed |
| EP-2450333-A1 | METHOD FOR PRODUCING ALICYCLIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238784-A1 | METHOD FOR PRODUCING ALICYCLIC ALCOHOL | ADH1C, ADH1A, ADH5 | FFAR3 145/4885NPSR1 4523/4885MAPT 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.